Bayer launches Aleve PM; Canada green-lights BMS' Yervoy;

> Bayer has launched Aleve PM, a pain reliever and sleep-aid combo. Release

> Health Canada has approved Bristol-Myers Squibb's ($BMY) Yervoy for first-line treatment of adults with metastatic melanoma. Release

> Novo Nordisk's ($NVO) new long-acting insulin, Tresiba, is effective and safe for long-term use in children and young adults with Type 1 diabetes, a new study shows. Report

> Danish drugmaker Lundbeck has launched antidepressant Brintellix in its home market, its first EU rollout. Report

> AbbVie ($ABBV) and Biogen Idec's ($BIIB) experimental multiple sclerosis med Zinbryta topped Biogen's Avonex on some measures in a Phase III trial. More

> Almost 90 lives could be saved every year if almost all teenage girls were given HPV vaccinations, experts say. More

And Finally... The U.S. government says Bayer makes unproven statements about the health benefits of a popular probiotic. More

Suggested Articles

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.